BX795 is primarily used in research settings as a potent inhibitor of TBK1 (TANK-binding kinase 1) and IKKε, two kinases involved in innate immune signaling pathways. It effectively suppresses the activation of IRF3 and NF-κB, which are key transcription factors in the production of type I interferons and pro-inflammatory cytokines. This makes BX795 a valuable tool for studying antiviral responses, inflammation, and autoimmune diseases. It has also been employed in cancer research due to its ability to modulate immune signaling in the tumor microenvironment. By inhibiting TBK1, BX795 can sensitize certain cancer cells to apoptosis and reduce survival signals in tumor cells that rely on aberrant NF-κB activity. Additionally, BX795 has shown potential in enhancing the efficacy of oncolytic viruses by blocking the host antiviral response, allowing for greater viral replication in tumor cells. Its role in autophagy modulation further extends its use in studying cellular stress responses and neurodegenerative disease models. Overall, BX795 serves as a critical pharmacological tool for dissecting signaling pathways related to immunity, inflammation, and cell survival.